Back to Browse Journals » Vascular Health and Risk Management » Volume 3 » Issue 6

A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications

Authors Behzad Molavi, Negah Rassouli, Suveer Bagwe, Neda Rasouli

Published 15 January 2008 Volume 2007:3(6) Pages 967—973

Behzad Molavi1, Negah Rassouli2, Suveer Bagwe1, Neda Rasouli2

Central Arkansas Veterans Healthcare System and University of Arkansas for Medical sciences, 1Division of cardiology and 2Division of Endocrinology, College of Medicine, Little Rock, Arkansas, USA

Abstract: The rising incidence of obesity and insulin resistance to epidemic proportions has closely paralleled the surge in the prevalence of diabetes and outpaced therapeutic advances in diabetes prevention and treatment. Current evidence points to obesity induced oxidative stress and chronic inflammation as the common denominators in the evolution of insulin resistance and diabetes. Of all the hypoglycemic agents in the pharmacological arsenal against diabetes, thiazolidinediones, in particular pioglitazone, as well as metformin appear to have additional effects in ameliorating oxidative stress and inflammation; rendering them attractive tools for prevention of insulin resistance and diabetes. In addition to their hypoglycemic and lipid modifying properties, pioglitazone and metformin have been shown to exert anti-oxidative and anti-inflammatory effects in vascular beds, potentially slowing the accelerated atherosclerosis in diabetes, which is the major cause of morbidity and mortality in the affected population. The combination of pioglitazone and metformin would thus appear to be an effective pharmacological intervention in prevention and treatment of diabetes. Finally, this review will address the currently available evidence on diabetic cardiomyopathy and the potential role of combination therapy with pioglitazone and metformin.

Keywords: insulin resistance, oxidative stress, inflammation, pioglitazone, metformin, atherosclerosis, diabetic cardiomyopathy

Download Article [PDF] 

Readers of this article also read:

Silica nanoparticles induce autophagy and endothelial dysfunction via the PI3K/Akt/mTOR signaling pathway

Duan J, Yu Y, Yu Y, Li Y, Wang J, Geng W, Jiang L, Li Q, Zhou X, Sun Z

International Journal of Nanomedicine 2014, 9:5131-5141

Published Date: 5 November 2014

Neutrophil/lymphocyte ratio in patients with atrial septal aneurysm

Demir M, Demir C

Vascular Health and Risk Management 2013, 9:365-368

Published Date: 19 July 2013


Teus MA, Miglior S, Laganovska G, Volksone L, Romanowska-Dixon B, Gos R, Holló G; for the C-05-25 Study Group

Clinical Ophthalmology 2011, 5:971-972

Published Date: 13 July 2011

Prevention of the renarrowing of coronary arteries using drug-eluting stents in the perioperative period: an update

Juan V Llau, Raquel Ferrandis, Pilar Sierra, et al

Vascular Health and Risk Management 2010, 6:855-867

Published Date: 29 September 2010

Recent achievements in the management of Raynaud’s phenomenon

Magnus Baumhäkel, Michael Böhm

Vascular Health and Risk Management 2010, 6:207-214

Published Date: 30 March 2010

Risk-assessment algorithm and recommendations for venous thromboembolism prophylaxis in medical patients

Ana T Rocha, Edison F Paiva, Arnaldo Lichtenstein, Rodolfo Milani Jr, Cyrillo Cavalheiro-Filho,
Francisco H Maffei

Vascular Health and Risk Management 2007, 3:533-553

Published Date: 15 September 2007

Combined use of brain natriuretic peptide and C-reactive protein for predicting cardiovascular risk in outpatients with type 2 diabetes mellitus

Toshihiro Tsuruda, Johji Kato, Takahiro Sumi, Kazuya Mishima, Hiroyuki Masuyama, Hiroyuki Nakao, Takuroh Imamura, Tanenao Eto, Kazuo Kitamura

Vascular Health and Risk Management 2007, 3:417-423

Published Date: 15 September 2007

Rosiglitazone and glimeperide: review of clinical results supporting a fixed dose combination

Andreas Pfützner, Birgit Wilhelm, Thomas Forst

Vascular Health and Risk Management 2007, 3:211-220

Published Date: 15 May 2007

Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes

John Pullman, Tamara Darsow, Juan P Frias

Vascular Health and Risk Management 2006, 2:203-212

Published Date: 15 September 2006

Valsartan in the treatment of heart attack survivors

Bodh I Jugdutt

Vascular Health and Risk Management 2006, 2:125-138

Published Date: 15 June 2006